Cowen & Co. Keeps a Buy Rating on G1 Therapeutics Inc (GTHX)

By Jason Carr

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on G1 Therapeutics Inc (GTHXResearch Report). The company’s shares opened today at $23.75.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 7.1% and a 44.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $63.50 average price target, implying a 167.4% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $72 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $69.57 and a one-year low of $13.87. Currently, G1 Therapeutics Inc has an average volume of 377.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.